Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.

Pecqueux C, Arslan A, Heller M, Falkenstein M, Kaczorowski A, Tolstov Y, Sültmann H, Grüllich C, Herpel E, Duensing A, Kristiansen G, Hohenfellner M, Navone NM, Duensing S.

Urol Oncol. 2018 Jun 7. pii: S1078-1439(18)30172-8. doi: 10.1016/j.urolonc.2018.05.020. [Epub ahead of print]

PMID:
29887238
2.

An in vivo screen identifies PYGO2 as a driver for metastatic prostate cancer.

Lu X, Pan X, Wu CJ, Zhao D, Feng S, Zang Y, Lee R, Khadka S, Amin SB, Jin EJ, Shang X, Deng P, Luo Y, Morgenlander WR, Weinrich J, Lu X, Jiang S, Chang Q, Navone NM, Troncoso P, DePinho RA, Wang YA.

Cancer Res. 2018 May 16. pii: canres.3564.2017. doi: 10.1158/0008-5472.CAN-17-3564. [Epub ahead of print]

PMID:
29769196
3.

Game-changing restraint of Ros-damaged phenylalanine, upon tumor metastasis.

Gueron G, Anselmino N, Chiarella P, Ortiz EG, Lage Vickers S, Paez AV, Giudice J, Contin MD, Leonardi D, Jaworski F, Manzano V, Strazza A, Montagna DR, Labanca E, Cotignola J, D Accorso N, Woloszynska-Read A, Navone N, Meiss RP, Ruggiero R, Vazquez E.

Cell Death Dis. 2018 Feb 2;9(2):140. doi: 10.1038/s41419-017-0147-8.

4.

Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.

Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC.

Clin Cancer Res. 2018 Feb 1;24(3):696-707. doi: 10.1158/1078-0432.CCR-17-1872. Epub 2017 Nov 14.

PMID:
29138344
5.

In Vivo Hemin Conditioning Targets the Vascular and Immunologic Compartments and Restrains Prostate Tumor Development.

Jaworski FM, Gentilini LD, Gueron G, Meiss RP, Ortiz EG, Berguer PM, Ahmed A, Navone N, Rabinovich GA, Compagno D, Laderach DJ, Vazquez ES.

Clin Cancer Res. 2017 Sep 1;23(17):5135-5148. doi: 10.1158/1078-0432.CCR-17-0112. Epub 2017 May 16.

PMID:
28512172
6.

A20 in Multiple Sclerosis and Parkinson's Disease: Clue to a Common Dysregulation of Anti-Inflammatory Pathways?

Perga S, Martire S, Montarolo F, Navone ND, Calvo A, Fuda G, Marchet A, Leotta D, Chiò A, Bertolotto A.

Neurotox Res. 2017 Jul;32(1):1-7. doi: 10.1007/s12640-017-9724-y. Epub 2017 Mar 23.

7.

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.

Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC.

Cell Rep. 2017 Feb 21;18(8):1970-1981. doi: 10.1016/j.celrep.2017.01.072.

8.

Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.

Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, Liang X, Chen JR, Shah S, Shang X, Tang M, Deng P, Dey P, Chakravarti D, Chen P, Spring DJ, Navone NM, Troncoso P, Zhang J, Wang YA, DePinho RA.

Nature. 2017 Feb 23;542(7642):484-488. doi: 10.1038/nature21357. Epub 2017 Feb 6.

9.

Heme oxygenase-1 in the forefront of a multi-molecular network that governs cell-cell contacts and filopodia-induced zippering in prostate cancer.

Paez AV, Pallavicini C, Schuster F, Valacco MP, Giudice J, Ortiz EG, Anselmino N, Labanca E, Binaghi M, Salierno M, Martí MA, Cotignola JH, Woloszynska-Read A, Bruno L, Levi V, Navone N, Vazquez ES, Gueron G.

Cell Death Dis. 2016 Dec 29;7(12):e2570. doi: 10.1038/cddis.2016.420.

10.

Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.

Ferrara F, Staquicini DI, Driessen WH, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG 2nd, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2016 Oct 24. pii: 201615400. [Epub ahead of print]

11.

A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients.

Martire S, Navone ND, Montarolo F, Perga S, Bertolotto A.

J Neuroimmunol. 2016 Mar 15;292:34-9. doi: 10.1016/j.jneuroim.2016.01.010. Epub 2016 Jan 16.

PMID:
26943956
12.

Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.

Kleb B, Estécio MR, Zhang J, Tzelepi V, Chung W, Jelinek J, Navone NM, Tahir S, Marquez VE, Issa JP, Maity S, Aparicio A.

Epigenetics. 2016 Mar 3;11(3):184-93. doi: 10.1080/15592294.2016.1146851. Epub 2016 Feb 18.

13.

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.

Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM.

Neoplasia. 2016 Jan;18(1):1-9. doi: 10.1016/j.neo.2015.11.009.

14.

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.

Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM.

Mol Cancer Res. 2016 Apr;14(4):324-31. doi: 10.1158/1541-7786.MCR-15-0472. Epub 2016 Jan 20.

15.

A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.

Fong EL, Wan X, Yang J, Morgado M, Mikos AG, Harrington DA, Navone NM, Farach-Carson MC.

Biomaterials. 2016 Jan;77:164-72. doi: 10.1016/j.biomaterials.2015.10.059. Epub 2015 Nov 9.

16.

Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.

Liu Z, Xu J, He J, Liu H, Lin P, Wan X, Navone NM, Tong Q, Kwak LW, Orlowski RZ, Yang J.

Oncotarget. 2015 Oct 27;6(33):34329-41. doi: 10.18632/oncotarget.6020.

17.

Association of HO-1 and BRCA1 Is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer.

Labanca E, De Luca P, Gueron G, Paez A, Moiola CP, Massillo C, Porretti J, Giudice J, Zalazar F, Navone N, Vazquez E, De Siervi A.

Mol Cancer Res. 2015 Nov;13(11):1455-64. doi: 10.1158/1541-7786.MCR-15-0150-T. Epub 2015 Jul 30.

18.

Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients.

Liu J, You P, Chen G, Fu X, Zeng X, Wang C, Huang Y, An L, Wan X, Navone N, Wu CL, McKeehan WL, Zhang Z, Zhong W, Wang F.

Oncogene. 2016 Apr 7;35(14):1750-9. doi: 10.1038/onc.2015.239. Epub 2015 Jun 22.

19.

PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.

Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8403-8. doi: 10.1073/pnas.1507882112. Epub 2015 Jun 15.

20.

Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.

Pasqualini R, Millikan RE, Christianson DR, Cardó-Vila M, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W.

Cancer. 2015 Jul 15;121(14):2411-21. doi: 10.1002/cncr.29344. Epub 2015 Apr 1.

21.

Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors.

Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3776-81. doi: 10.1073/pnas.1500128112. Epub 2015 Mar 11.

22.

Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.

Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM.

Sci Transl Med. 2014 Sep 3;6(252):252ra122. doi: 10.1126/scitranslmed.3009332. Erratum in: Sci Transl Med. 2015 May 13;7(287):287er3. Tapia, Elsa M Li-Ning [corrected to Li Ning Tapia, Elsa M].

23.

Heme-oxygenase-1 implications in cell morphology and the adhesive behavior of prostate cancer cells.

Gueron G, Giudice J, Valacco P, Paez A, Elguero B, Toscani M, Jaworski F, Leskow FC, Cotignola J, Marti M, Binaghi M, Navone N, Vazquez E.

Oncotarget. 2014 Jun 30;5(12):4087-102.

24.

Monocytes and CD4+ T cells contribution to the under-expression of NR4A2 and TNFAIP3 genes in patients with multiple sclerosis.

Navone ND, Perga S, Martire S, Berchialla P, Malucchi S, Bertolotto A.

J Neuroimmunol. 2014 Jul 15;272(1-2):99-102. doi: 10.1016/j.jneuroim.2014.04.017. Epub 2014 May 10.

25.

Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.

Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC.

Sci Signal. 2014 May 20;7(326):ra47. doi: 10.1126/scisignal.2005070.

26.

Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening.

Fong EL, Martinez M, Yang J, Mikos AG, Navone NM, Harrington DA, Farach-Carson MC.

Mol Pharm. 2014 Jul 7;11(7):2040-50. doi: 10.1021/mp500085p. Epub 2014 Apr 29.

27.

PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.

Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY.

Cancer Res. 2014 Mar 15;74(6):1651-60. doi: 10.1158/0008-5472.CAN-13-3159. Epub 2014 Jan 28.

28.

Heme oxygenase-1 (HO-1) expression in prostate cancer cells modulates the oxidative response in bone cells.

Ferrando M, Wan X, Meiss R, Yang J, De Siervi A, Navone N, Vazquez E.

PLoS One. 2013 Nov 4;8(11):e80315. doi: 10.1371/journal.pone.0080315. eCollection 2013.

29.

Targeting fibroblast growth factor pathways in prostate cancer.

Corn PG, Wang F, McKeehan WL, Navone N.

Clin Cancer Res. 2013 Nov 1;19(21):5856-66. doi: 10.1158/1078-0432.CCR-13-1550. Epub 2013 Sep 19. Review.

30.

Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation.

Elguero B, Gueron G, Giudice J, Toscani MA, De Luca P, Zalazar F, Coluccio-Leskow F, Meiss R, Navone N, De Siervi A, Vazquez E.

Neoplasia. 2012 Nov;14(11):1043-56.

31.

Glutathione-S-transferase (GST) polymorphisms are associated with relapse after radical prostatectomy.

Cotignola J, Leonardi DB, Shahabi A, Acuña AD, Stern MC, Navone N, Scorticati C, De Siervi A, Mazza O, Vazquez E.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):28-34. doi: 10.1038/pcan.2012.45. Epub 2012 Nov 13.

32.

Arachidonic acid metabolism in human prostate cancer.

Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim J.

Int J Oncol. 2012 Oct;41(4):1495-503. doi: 10.3892/ijo.2012.1588. Epub 2012 Aug 10.

33.

Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response.

Gilli F, Navone ND, Valentino P, Granieri L, Perga S, Malucchi S, Bertolotto A.

Mult Scler. 2012 Oct;18(10):1484-92. Epub 2012 May 4.

PMID:
22562951
34.

Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.

Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E.

Prostate. 2012 Nov;72(15):1638-47. doi: 10.1002/pros.22517. Epub 2012 Mar 27.

35.

Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.

Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q.

Leukemia. 2012 Sep;26(9):2114-23. doi: 10.1038/leu.2012.71. Epub 2012 Mar 19. Erratum in: Leukemia. 2015 Feb;29(2):515.

36.

Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer.

Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian A, Efstathiou E, Navone N, Troncoso P, Zhang W.

PLoS One. 2012;7(2):e31259. doi: 10.1371/journal.pone.0031259. Epub 2012 Feb 17.

37.

Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM.

Clin Cancer Res. 2012 Feb 1;18(3):726-36. doi: 10.1158/1078-0432.CCR-11-2521.

38.

Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.

Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone N, Zhang W.

Am J Pathol. 2012 Mar;180(3):895-903. doi: 10.1016/j.ajpath.2011.11.030. Epub 2012 Jan 11.

39.

Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.

Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J.

PLoS One. 2011;6(12):e28840. doi: 10.1371/journal.pone.0028840. Epub 2011 Dec 14.

40.

Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.

Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, Kundra V, Vazquez E, Navone NM.

Bone. 2012 Mar;50(3):695-703. doi: 10.1016/j.bone.2011.11.022. Epub 2011 Dec 7.

41.

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM.

Clin Cancer Res. 2012 Feb 1;18(3):666-77. doi: 10.1158/1078-0432.CCR-11-1867. Epub 2011 Dec 12.

42.

Vascular patterning and permeability in prostate cancer models with differing osteogenic properties.

Dafni H, Burghardt AJ, Majumdar S, Navone NM, Ronen SM.

NMR Biomed. 2012 Jun;25(6):843-51. doi: 10.1002/nbm.1800. Epub 2011 Dec 2.

PMID:
22134886
43.

Personalized oncology through integrative high-throughput sequencing: a pilot study.

Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM.

Sci Transl Med. 2011 Nov 30;3(111):111ra121. doi: 10.1126/scitranslmed.3003161.

44.

Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer.

Ferrando M, Gueron G, Elguero B, Giudice J, Salles A, Leskow FC, Jares-Erijman EA, Colombo L, Meiss R, Navone N, De Siervi A, Vazquez E.

Angiogenesis. 2011 Dec;14(4):467-79. doi: 10.1007/s10456-011-9230-4. Epub 2011 Aug 11.

PMID:
21833623
45.

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM.

Cancer Cell. 2011 May 17;19(5):664-78. doi: 10.1016/j.ccr.2011.04.010. Erratum in: Cancer Cell. 2013 Apr 15;23(4):557.

46.

Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles.

Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN.

Prostate. 2011 Jun 1;71(8):846-56. doi: 10.1002/pros.21301. Epub 2010 Nov 17.

47.

Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosis.

Gilli F, Navone ND, Perga S, Marnetto F, Caldano M, Capobianco M, Pulizzi A, Malucchi S, Bertolotto A.

Arch Neurol. 2011 Jul;68(7):879-88. doi: 10.1001/archneurol.2011.32. Epub 2011 Mar 14.

PMID:
21403007
48.

Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM.

Clin Cancer Res. 2011 Apr 15;17(8):2328-38. doi: 10.1158/1078-0432.CCR-10-2943. Epub 2011 Feb 22.

49.

Prioritizing genes associated with prostate cancer development.

Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ.

BMC Cancer. 2010 Nov 2;10:599. doi: 10.1186/1471-2407-10-599.

50.

TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.

Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA.

Hum Pathol. 2011 Jan;42(1):11-7. doi: 10.1016/j.humpath.2010.05.026. Epub 2010 Oct 30.

Supplemental Content

Loading ...
Support Center